Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.

Molecular cancer therapeutics - 1 Dec 2014

Macleod Alison C, Klug Lillian R, Patterson Janice, Griffith Diana J, Beadling Carol, Town Ajia, Heinrich Michael C

Abstract excerpt

Resistant KIT mutations have hindered the development of KIT kinase inhibitors for treatment of patients with systemic mastocytosis. The goal of this research was to characterize the synergistic effects of a novel combination therapy involving inhibition of KIT and calcineurin phosphatase, a nucl...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcineurin
Share to Calcineurin Inhibitors
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Mast Cells

Share to NFATC Transcription Factors

Share to Proto-Oncogene Proteins c-kit

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 25253785
DOI: 10.1158/1535-7163.MCT-13-0830
PMCID: PMC5026483

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25253785-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.PMID 25253785Read ↗

Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation.Semantic proximity Read ↗

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.Semantic proximity Read ↗

TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases.Semantic proximity Read ↗

Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells.Semantic proximity Read ↗

Negative regulation of mast cell proliferation by FcgammaRIIB.Semantic proximity Read ↗

Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930.Semantic proximity Read ↗

Negative Cross Talk between NFAT1 and Stat5 Signaling in Breast CancerSemantic proximity Read ↗

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.